| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | Calidi Biotherapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 19.09. | Calidi Biotherapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 29.08. | Calidi Biotherapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 22.08. | Calidi Biotherapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 22.08. | Calidi Biotherapeutics closes $6.9 million public offering | 2 | Investing.com | ||
| 22.08. | Calidi Biotherapeutics, Inc: Calidi Biotherapeutics Announces Closing of $6.9 Million Underwritten Public Offering and Full Exercise of Underwriters' Over-Allotment Option | 2 | GlobeNewswire (USA) | ||
| 20.08. | Calidi Biotherapeutics, Inc: Calidi Biotherapeutics Announces Pricing of $6 Million Underwritten Public Offering | 3 | GlobeNewswire (USA) | ||
| CALIDI BIOTHERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 15.08. | Calidi files to sell 1.2M common stock units | 1 | Seeking Alpha | ||
| 15.08. | Calidi Biotherapeutics, Inc. - S-1, General form for registration of securities | 1 | SEC Filings | ||
| 14.08. | Calidi Biotherapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 11.08. | Calidi Biotherapeutics GAAP EPS of -$1.99 | 1 | Seeking Alpha | ||
| 08.08. | Calidi Biotherapeutics, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 08.08. | Calidi Biotherapeutics, Inc: Calidi Biotherapeutics Reports Second Quarter 2025 Financial Results and Recent Operational Highlights | 249 | GlobeNewswire (Europe) | Presented preclinical data at the American Society of Clinical Oncology (ASCO) on CLD-401 demonstrating biological efficacy IL-15 superagonist delivery to metastatic tumor sites and reduced immune... ► Artikel lesen | |
| 07.08. | Calidi Biotherapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 01.08. | RedChip Companies, Inc.: Atossa Therapeutics and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money Show on Bloomberg TV | 537 | ACCESS Newswire | ORLANDO, FL / ACCESS Newswire / August 1, 2025 / RedChip Companies will air interviews with Calidi Biotherapeutics, Inc. (NYSE American:CLDI) and Atossa Therapeutics, Inc. (Nasdaq:ATOS) on the RedChip... ► Artikel lesen | |
| 29.07. | FDA grants fast track designation to Calidi's CLD-201 for sarcoma | 3 | Investing.com | ||
| 25.07. | Calidi announces reverse stock split, expected to begin trading on a 1-for-12 split adjusted basis | 4 | Seeking Alpha | ||
| 25.07. | Calidi Biotherapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 25.07. | Calidi Biotherapeutics, Inc: Calidi announces Reverse Stock Split, expected to begin trading on a 1-for-12 split adjusted basis on August 5, 2025 | 291 | GlobeNewswire (Europe) | SAN DIEGO, July 25, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. ("Calidi" or the "Company") (NYSE American: CLDI), a clinical-stage biotechnology company pioneering the development of targeted... ► Artikel lesen | |
| 22.07. | Calidi Biotherapeutics, Inc: Join Calidi Biotherapeutics' Exclusive Live Investor Webinar and Q&A Session on July 24 | 2 | GlobeNewswire (USA) |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 90,75 | -0,33 % | PRESSESPIEGEL/Unternehmen: LEG, DEUTSCHE BAHN, FLINK, BIONTECH/CUREVAC, NEURAXPHARM | DJ PRESSESPIEGEL/Unternehmen
Die wirtschaftsrelevanten Themen aus den Medien, zusammengestellt von Dow Jones Newswires.
LEG - Der Chef des zweitgrößten deutschen Vermieters LEG, Lars von Lackum... ► Artikel lesen | |
| MODERNA | 23,045 | -0,09 % | Tesla- & IBM-Bilanzen enttäuschen - D-Wave, Moderna, Honeywell, T-Mobile US | Nach dem Rekordlauf vom Dienstag haben die Anleger an der Wall Street am Mittwoch Kasse gemacht. Der Dow Jones verlor zum Handelsschluss 0,71 Prozent. Besonders deutlich fiel die Korrektur im Technologiesektor... ► Artikel lesen | |
| OCUGEN | 1,370 | +1,26 % | Ocugen to Host Webcast on Wednesday, November 5 at 8:30 A.M. ET to Discuss Business Updates and Third Quarter 2025 Financial Results | ||
| VIKING THERAPEUTICS | 30,950 | +0,60 % | Viking Therapeutics-Aktie: Die spannendste Adipositas-Wette? | Nach unserem letzten Kauftipp Ende vergangenen Monats hat die Aktie von Viking Therapeutics wieder Fahrt aufgenommen und konnte über 20% zulegen. Vor den kommenden Quartalszahlen kocht die Spannung... ► Artikel lesen | |
| ABCELLERA BIOLOGICS | 4,928 | +0,04 % | Why Did AbCellera's Stock Jump Over 7% After Hours? | ||
| ADAPTIMMUNE THERAPEUTICS | 0,030 | -33,33 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 21.10.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 21.10.2025.Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 21.10.2025.ISIN NameCA80013R2063 SANDSTORM... ► Artikel lesen | |
| SAGIMET BIOSCIENCES | 7,300 | -1,35 % | Sagimet rises after denifanstat succeeds in late stage trial | ||
| AVIDITY BIOSCIENCES | 69,97 | +42,36 % | Novartis will US-Biotech Avidity Biosciences für 12 Mrd USD übernehmen | DJ Novartis will US-Biotech Avidity Biosciences für 12 Mrd USD übernehmen
Von Dylan Tokar und Peter Loftus
DOW JONES--Novartis will den US-Biotech-Konzern Avidity Biosciences für 12 Milliarden... ► Artikel lesen | |
| QIAGEN | 41,860 | -1,29 % | QIAGEN N.V. to Release Results for Q3 2025 and Hold Webcast | QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) today announced plans to release results for the third quarter of 2025.
Press release date time: Tuesday, November 4, shortly after 22:05... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 6,290 | 0,00 % | Recursion Pharmaceuticals (RXRX) Surges 14% Ahead of Earnings | ||
| EVOTEC | 7,124 | +2,18 % | Aktien Frankfurt: Solide Zahlen aus den USA schieben Kurse an | FRANKFURT (dpa-AFX) - Überwiegend robuste Quartalsbilanzen und Prognosen von US-Unternehmen haben dem deutschen Aktienmarkt am Dienstag etwas Anschub verliehen. Der Leitindex Dax, der sich bis zum... ► Artikel lesen | |
| DYNE THERAPEUTICS | 24,170 | 0,00 % | Why Dyne Therapeutics Stock Crushed the Market on Monday | ||
| MAPLIGHT THERAPEUTICS | 18,050 | 0,00 % | MapLight Therapeutics Prices IPO Of 14.75 Mln Shares At $17.00/shr | WASHINGTON (dpa-AFX) - MapLight Therapeutics Inc., a clinical-stage biopharmaceutical company focused on
improving the lives of patients suffering from debilitating central nervous
system... ► Artikel lesen | |
| NUVALENT | 97,95 | +4,88 % | Piper Sandler erhöht Kursziel für Nuvalent auf 128 US-Dollar wegen ALK-Potenzial | ||
| BEAM THERAPEUTICS | 26,710 | 0,00 % | Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease | CAMBRIDGE, Mass., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that... ► Artikel lesen |